Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine.
A sensitive high-performance liquid chromatographic (HPLC) method is described for the determination of a new potent antihypertensive agent, TCV-116, and its two metabolites (M-I and M-II) in human serum or urine. After pre-treatment of the specimens, the analytes were determined using a column switching technique, except for the metabolites in urine which were determined by gradient elution mode HPLC. The quantitation limits for TCV-116, M-I and M-II were all 0.5 ng/ml in serum, and 0.5, 10 and 110 ng/ml in urine, respectively. The methods were applied to clinical trials of TCV-116.
Miyabayashi
T
T
Drug Analysis and Pharmacokinetics Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Okuda
T
T
Motohashi
M
M
Izawa
K
K
Yashiki
T
T
D000804:Angiotensin II / Q000378:metabolism*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000032:analysis* / Q000097:blood / Q000652:urine; D001562:Benzimidazoles / Q000032:analysis* / Q000097:blood / Q000652:urine; D001713:Biphenyl Compounds / Q000032:analysis* / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007202:Indicators and Reagents; D008297:Male; D011355:Prodrugs / Q000032:analysis*; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet; D013777:Tetrazoles
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007202:Indicators and Reagents; D011355:Prodrugs; D013777:Tetrazoles; D000804:Angiotensin II; C077793:candesartan cilexetil